Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012Cited by 12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationPaul B. Chapman, Grant A. McArthur, Axel Hauschild et al.|New England Journal of Medicine|2011Cited by 7.7k
Inhibition of Mutated, Activated BRAF in Metastatic MelanomaKeith T. Flaherty, Paul B. Chapman, Igor Puzanov et al.|New England Journal of Medicine|2010Cited by 3.5k
Fulminant Myocarditis with Combination Immune Checkpoint BlockadeDouglas B. Johnson, Javid J. Moslehi, Justin M. Balko et al.|New England Journal of Medicine|2016Cited by 2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L. Topalian, F. Stephen Hodi, Mario Sznol et al.|Journal of Clinical Oncology|2014Cited by 2.2k